Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial - Test2 - elhamkhani - TriplyDB

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

http://www.wikidata.org/entity/Q28236008

about

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies Cancer as an evolutionary and ecological process HPV and Cervical Cancer: Updates on an Established Relationship Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future.Vaccination greatly reduces disease, disability, death and inequity worldwide Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States Human papillomavirus and HPV vaccines: a review Role of the microbiome in non-gastrointestinal cancers Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease Vaccine Adjuvants: from 1920 to 2015 and Beyond Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV An appraisal of theoretical approaches to examining behaviours in relation to Human Papillomavirus (HPV) vaccination of young women Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus Verruca vulgaris of the tongue: a case report with a literature review The criteria to confirm the role of Epstein-Barr virus in nasopharyngeal carcinoma initiation Discussing the diagnosis of HPV-OSCC: common questions and answers Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins HPV vaccine: Current status and future directions HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know Safety of human papillomavirus vaccines: a review Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong Kong Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial Safety of human papillomavirus vaccines: a review.Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.Prognostic value of histopathology and trends in cervical cancer: a SEER population study Evaluating human papillomavirus vaccination programs in Canada: should provincial healthcare pay for voluntary adult vaccination?Human Papillomavirus type distribution in invasive cervical cancer in Uganda Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Genotype distribution of human papillomavirus (HPV) and co-infections in cervical cytologic specimens from two outpatient gynecological clinics in a region of southeast Spain A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan.

P2860

Q21129302-49651E10-2E05-4937-A0C9-DF0854D1225A Q22122026-86B0F116-C206-408C-9193-36A71B30A042 Q22305479-C4E5DE48-FC21-443F-B2C4-8F758CF7762C Q24600011-3555E591-FF6E-4BD0-BAA3-74040AE5560A Q24648884-9589109E-D780-42D8-BA30-946C8EC9B5C7 Q24655328-05B884D2-AFC8-458D-982C-5110ED497251 Q24657891-ECA38FD5-2787-4A4D-BC1E-961677E9D58F Q26747710-176A5DF2-AA97-4DE4-873F-6EB155D8F25B Q26749285-D5E8A665-9FC8-4E91-AAE3-20F4FDB136D4 Q26777330-B7E0EF68-5459-4FE9-BF7F-BC733165F5FD Q26783879-9FFE51DA-BD18-4529-ACEF-C5DCD4056820 Q26783973-5D6C14BC-B460-4CF9-8836-2839981F439D Q26796532-89962353-15F2-4FA5-A8BB-C3AC357D91DB Q26799574-86661097-EC26-4B31-9E5C-EBEA2B38885F Q26822914-C8F30373-5EED-4F49-A225-4247C48F47C9 Q26853527-6F6AD272-B7C6-45A0-BF02-7BA9BC3F6738 Q27000693-8A34F079-4B2E-47E4-BF26-7E52F0EBE44C Q27013018-24EEF4BD-134F-449B-A6B1-DB4B4488DC8D Q27026524-19C8E8D6-22E3-4E83-B9A5-1CD1C6DF893E Q28072958-5F97CF22-BA6F-422E-9378-797A0FFC608C Q28082119-5020E137-B2DC-410A-8D65-F923E17EB17B Q28085724-4FDA684E-0AD1-4D90-893D-2B73B2BAB92B Q28246307-21A871C9-7DD1-4B0F-BBD1-500AB8FE6198 Q28280059-CFA04FD4-034A-4DBA-8AC6-053D51DCC841 Q28607942-A2D8AFD9-5236-4175-ACA3-B01A1BC51DE4 Q30573204-467E6205-DA83-451F-AC93-C768660C4180 Q30780649-2675C37D-2B66-44C8-9D5E-F5B4F53319D4 Q30980654-C6F429C5-1158-455B-9FA0-B0B23D2B8505 Q31044179-2EF3D282-0006-47E5-AC1E-D353D2BD7784 Q31131825-1F5FCDA2-29F9-4F25-B969-AD21A7C05748 Q31151637-B73C3C96-3C2B-4BD4-A986-179C304F90D7 Q33162724-055AF302-8805-4FC4-95ED-202A644048D0 Q33292779-99A9F7DE-13B6-41F6-9208-FE85800C568A Q33295075-07F49CE0-70F1-4098-B764-843591525BD6 Q33327567-005968ED-A239-40C5-8BCB-E632796CD1AE Q33346465-63390F39-EBF9-48A8-9D13-3ABDEB590DA8 Q33346685-C3A849F7-A102-4B5C-B0C4-E4DC8CEFE524 Q33491832-21EE6B1E-4845-4852-B5D0-67BEF5EA98FD Q33514126-F027EDE3-1E1B-4BFB-97F0-635B787105CA Q33523171-F0A13FB4-5E66-43BA-83F0-A6EBCFE944F1

P2860

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

http://www.wikidata.org/entity/Q28236008

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Sustained efficacy up to 4.5 y ...... rom a randomised control trial

@ast

Sustained efficacy up to 4.5 y ...... rom a randomised control trial

@en

Sustained efficacy up to 4.5 y ...... rom a randomised control trial

@nl

type

label

Sustained efficacy up to 4.5 y ...... rom a randomised control trial

@ast

Sustained efficacy up to 4.5 y ...... rom a randomised control trial

@en

Sustained efficacy up to 4.5 y ...... rom a randomised control trial

@nl

prefLabel

Sustained efficacy up to 4.5 y ...... rom a randomised control trial

@ast

Sustained efficacy up to 4.5 y ...... rom a randomised control trial

@en

Sustained efficacy up to 4.5 y ...... rom a randomised control trial

@nl

P1433

Q28236008-EBE8D7F8-3438-4595-9E67-9190A83E1A39

P1476

Q28236008-49F08F20-5506-4DEF-B619-CBA429DB336B

P2093

Q28236008-2288789C-6CC1-400F-B36B-EFDA204628E2

Q28236008-23E1B775-333E-40A1-949B-A30D7EBA6CE2

Q28236008-3A8148A4-5A9C-412D-88D5-2BECB34DDE05

Q28236008-3C97A34E-2A5D-4884-A30F-4E6419A7A562

Q28236008-3E243E84-7ABF-4196-88CC-22A34F93A554

Q28236008-588B472A-1818-45E8-818D-F360FCDB6096

Q28236008-90FAC097-26E1-4171-B8D6-45C3D63485FC

Q28236008-9A82B668-4A64-416A-90D1-71322D735C42

P304

Q28236008-F99A3F10-E425-4371-80C0-F71DCC3FF1DD

P31

Q28236008-B72935E5-1F46-4B9E-87D8-38C08944CF8E

P3181

Q28236008-D96E9A90-1F02-4567-A755-43AAE0DF09B8

P356

Q28236008-6FCC9612-4476-4E45-8E7E-994BF05B0159

P407

Q28236008-424F3112-3E78-43B7-8764-C1A2C2EE9ED4

P433

Q28236008-E456C077-4363-48BC-9121-85C89E8E5050

P478

Q28236008-CB7AF69B-BBCB-4B5C-8133-BD93985A0C81

P50

Q28236008-BB8FB879-F9E3-402C-80CA-E196F3D227E7

Q28236008-E763C4FB-813C-4F78-94D0-52A838FE5B93

P577

Q28236008-3EC56A35-C068-4DEB-B620-02976E162CDE

P698

Q28236008-8D231D71-6AFF-45DD-9AA8-198DA2387F47

P3181

P356

S0140-6736(06)68439-0

P1433

P1476

Sustained efficacy up to 4.5 y ...... rom a randomised control trial

@en

P2093

Anna-Barbara Moscicki

http://www.w3.org/2001/XMLSchema#string

Anne Schuind

http://www.w3.org/2001/XMLSchema#string

Barbara Romanowski

http://www.w3.org/2001/XMLSchema#string

Cecilia M Roteli-Martins

http://www.w3.org/2001/XMLSchema#string

David Jenkins

http://www.w3.org/2001/XMLSchema#string

Diane M Harper

http://www.w3.org/2001/XMLSchema#string

Gary Dubin

http://www.w3.org/2001/XMLSchema#string

Sue Ann Costa Clemens

http://www.w3.org/2001/XMLSchema#string

P304

1247-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1123014

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(06)68439-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

9518

http://www.w3.org/2001/XMLSchema#string

P478

367

http://www.w3.org/2001/XMLSchema#string

P50

Eduardo L. Franco

Cosette M Wheeler

P577

2006-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16631880

http://www.w3.org/2001/XMLSchema#string